Abstract 351P
Background
Waldenstrom macroglobulinemia (WM) is a very rare disease. It also known as lymphoplasmacytic lymphoma, a low grade-B cell lymphoproliferative neoplasm characterized by monoclonal IgM gammopathy. The diagnosis of WM is challenging and data regarding clinical features and treatment outcomes in Indonesia is limited. The aim of this study is to investigate clinical features, treatments and outcomes of WM patients in the tertiary referral cancer center in Jakarta, Indonesia.
Methods
This was a retrospective cohort study conducted in outpatient oncology clinic in a tertiary referral cancer center in Jakarta, Indonesia from 2022 until 2023. It included all patients with working diagnosis WM based on Waldenstrom Macroglobulinemia International Workshop Criteria. Demographic data, clinical features, treatments, and outcomes were collected.
Results
We evaluated a total of 8 patients. Most of the patients (62.5%) were male, with mean age 61.1 + 8.6 years old. All patients had symptoms of anemia such weakness, light-headedness, and shortness of breath. Median hemoglobin was 8.46 (6.0 – 13.1) g/dL. Mean immunoglobulin (Ig)M was 3832. Three (37.5%) patients had autoimmune hemolytic anemia (AIHA), and 3 (37.5%) patients had organomegaly. Seventy percent patients received systemic therapy, mostly (66.7%) with Cyclophosphamide Vincristine Prednisone (CVP) regiment. Among those who had systemic therapy, two (33.3%) patients died, and 1 (16.6%) patient transformed into acute myeloid leukemia (AML).
Conclusions
The clinical features of WM were male sex, elderly, anemia, had AIHA, high IgM and organomegaly. Most patients underwent systemic therapy but had unfavorable responses. Further studies should focus on predictors of survival on WM patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
111P - Comparison of the efficacy and safety of fruquintinib and fruquintinib combined with immune checkpoint inhibitors in the treatment of metastatic microsatellite stable colorectal cancer: A real-world study
Presenter: Zhiqiang Wang
Session: Poster Display
Resources:
Abstract
112P - Optimal classification and treatment strategy based on technical and oncological futures in recurrence of colorectal liver metastases
Presenter: Kosuke Kobayashi
Session: Poster Display
Resources:
Abstract
113P - Phase I/II study of capecitabine(C)/oxaliplatin(O)/irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
Presenter: Kai Ou
Session: Poster Display
Resources:
Abstract
114P - The prognostic role of LAG-3 expression in metastatic colorectal cancer
Presenter: Yi-Hsuan Huang
Session: Poster Display
Resources:
Abstract
115P - Sidedness and survival of chemo-refractory metastatic colorectal cancer treated with lonsurf or regorafenib: A nationwide population-based study in Taiwan
Presenter: Meng-Che Hsieh
Session: Poster Display
Resources:
Abstract
116P - Burden and trends of colorectal cancer in high income Asia Pacific countries from 1990-2019 and its projections of deaths to 2040: A comparative analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
117P - Australasian real-world treatment selection and clinical outcomes for patients with left side (LS), RAS wildtype (RASwt) metastatic colorectal cancer (mCRC)
Presenter: Vanessa Wong
Session: Poster Display
Resources:
Abstract
119P - Neoadjuvant chemoradiotherapy in the mode of hypofractionation in locally advanced rectal cancer: Is it time to change standards of care?
Presenter: Abror Abdujapparov
Session: Poster Display
Resources:
Abstract
120P - Improved clinical outcomes with cetuximab maintenance therapy in left-sided RAS/BRAF wild-type metastatic colorectal cancer: A real-world study of Hunan cancer hospital
Presenter: Xiaolin Yang
Session: Poster Display
Resources:
Abstract
121P - Single-cell sequencing reveals the role of Treg cells with high expression of BIRC3 in regulating the progression of colorectal cancer
Presenter: Yuqiu Xu
Session: Poster Display
Resources:
Abstract